Review Decision – January 2016

Review of NICE Technology Appraisal Guidance No. 272; Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract

Decision to move the existing guidance to the ‘static list’ – January 2016

The Institute was proposing that the guidance should be transferred to the ‘static guidance’ list.

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

TA272 will therefore move to the ‘static guidance’ list. Topics on the static list can be considered for review if any new evidence becomes available that is likely to lead to a change in the existing recommendations.

Appendix A – RPP decision paper – December 2015

This page was last updated: